Is candidiasis considered a sexually transmitted infection, and what are the recommended first‑line treatments and partner management for an otherwise healthy adult with an uncomplicated episode?

Is Candidiasis Sexually Transmitted?

Vulvovaginal candidiasis is not classified as a sexually transmitted infection, and routine partner treatment is not recommended because it does not reduce recurrence rates. 1, 2

Classification as Non-STI

• The CDC explicitly excludes vulvovaginal candidiasis from the category of sexually transmitted diseases, despite occasional sexual transmission occurring during vaginal or orogenital contact. 3, 4

• Approximately 10–20% of women normally harbor Candida species in the vagina without infection, representing asymptomatic colonization rather than sexually transmitted disease. 1

• Genetic typing studies demonstrate that only 17.2% of heterosexual couples harbor genetically identical Candida strains, arguing against sexual transmission as a primary mechanism. 5

• Women with recurrent vulvovaginal candidiasis (RVVC) are significantly more likely to have Candida-negative sexual partners (83.3% negative) compared to women with sporadic episodes (31.8% negative), further refuting the sexual reservoir hypothesis. 5

First-Line Treatment for Uncomplicated Episodes

For an otherwise healthy adult with uncomplicated vulvovaginal candidiasis, prescribe either oral fluconazole 150 mg as a single dose or a short-course (3–7 day) topical azole regimen; both achieve cure rates exceeding 90%. 1, 6

Oral Option

• Fluconazole 150 mg orally as a single dose offers superior convenience and equivalent efficacy to topical agents. 1, 6

Topical Options (3-day regimens)

• Miconazole 200 mg vaginal suppository once daily for 3 days 1
• Terconazole 0.8% cream 5 g intravaginally once daily for 3 days 1
• Terconazole 80 mg vaginal suppository once daily for 3 days 1

Topical Options (7-day regimens)

• Clotrimazole 1% cream 5 g intravaginally once daily for 7 days 1, 2
• Miconazole 2% cream 5 g intravaginally once daily for 7 days 1, 2
• Terconazole 0.4% cream 5 g intravaginally once daily for 7 days 1, 2

Diagnostic Confirmation Before Treatment

• Obtain wet-mount microscopy with 10% potassium hydroxide to visualize budding yeast or pseudohyphae; this test is positive in 50–70% of true cases. 1, 2

• Measure vaginal pH with narrow-range pH paper; a pH ≤ 4.5 supports vulvovaginal candidiasis, whereas pH > 4.5 suggests bacterial vaginosis or trichomoniasis. 1, 2

• Self-diagnosis is unreliable—women incorrectly self-diagnose yeast infection in the majority of cases—so microscopic confirmation is essential before initiating therapy. 1, 6

Partner Management

Do not treat sexual partners routinely; partner treatment is indicated only if the male partner exhibits symptomatic balanitis (erythema and pruritus of the glans). 1, 2

• Treating asymptomatic male partners does not reduce recurrence rates in women with sporadic vulvovaginal candidiasis. 1, 2

• One older cohort study reported lower recurrence when colonized male partners were treated (15.8% vs. 44.8%), but this finding has not been replicated in subsequent research and contradicts genetic typing data showing lack of strain concordance. 7

• For women with true recurrent vulvovaginal candidiasis (≥4 episodes per year), male partners are less likely to harbor Candida, making partner treatment even less relevant. 5

When to Extend Therapy Beyond Single-Dose Regimens

• Avoid single-dose regimens when marked vulvar erythema, edema, excoriation, or fissuring is present; instead, prescribe topical azole therapy for 7–14 days or fluconazole 150 mg every 72 hours for 2–3 doses. 1, 6

• Reserve single-dose treatments for uncomplicated mild-to-moderate disease only; complicated infections (severe symptoms, immunosuppression, uncontrolled diabetes, pregnancy, or non-albicans species) require extended therapy. 1, 6

Management of Recurrent Vulvovaginal Candidiasis

If the patient experiences ≥4 episodes within 12 months, implement a two-phase regimen:

Induction Phase (10–14 days)

• Either a daily topical azole regimen (any of the 7-day options listed above, extended to 10–14 days) or fluconazole 150 mg orally with a repeat dose after 72 hours. 1, 6

Maintenance Phase (6 months)

• Fluconazole 150 mg orally once weekly for 6 months achieves symptom control in >90% of patients during treatment. 1, 6

• After discontinuation of the 6-month maintenance course, a recurrence rate of 40–50% should be anticipated. 1

Critical Pitfalls to Avoid

• Do not treat asymptomatic Candida colonization—even if yeast is visualized on microscopy—because 10–20% of women normally harbor Candida without infection. 1, 2

• Do not initiate therapy without microscopic confirmation because clinical symptoms overlap significantly with bacterial vaginosis and trichomoniasis, which require entirely different treatments. 1, 2

• Do not recommend over-the-counter self-medication unless the patient has a prior physician-confirmed diagnosis of vulvovaginal candidiasis and experiences identical recurrent symptoms. 1, 2

• Do not treat sexual partners routinely; this practice wastes resources and does not reduce recurrence. 1, 2

Special Populations

• HIV-positive women should receive identical treatment regimens as HIV-negative women; response rates are equivalent and no modification based solely on HIV status is required. 1, 6

• Pregnant women must use only 7-day topical azole therapy; oral fluconazole is contraindicated due to associations with spontaneous abortion and congenital malformations. 1, 6

Follow-Up Recommendations

• Advise patients to seek follow-up only if symptoms persist after completing therapy or recur within 2 months. 1, 6

• If symptoms persist despite appropriate therapy, obtain vaginal culture to identify non-albicans species (especially Candida glabrata, which accounts for 10–20% of recurrent cases and shows reduced susceptibility to standard azoles). 1, 8